TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01852669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydration
Description: Hydration of patient with 0.5L NaCl and 20mg frusemide IV
Study: NCT04854421

Intervention type: DEVICE
Intervention: VBC
Description: Body Composition will be measured using the VBC system that takes under 60 seconds per scan. Image capture for VBC will include taking a series of four photos using a smartphone camera. Data from the camera will be downloaded to a local computer and then securely sent to the cloud for automated analysis and results generation. We will conduct two consecutive scans (image captures) for each research participant.
Study: NCT01785251

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation
Description: Applied using a custom built, medically approved stimulator called the Duo-STIM. NMES to be applied to the calf muscles to elicit a muscular contraction to eject blood through the venous system.
Study: NCT02760849

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oophorectomy
Description: Undergo ISDO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Salpingectomy
Description: Undergo ISDO

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Salpingo-Oophorectomy
Description: Undergo RRSO
Study: NCT03054675

Intervention type: DIAGNOSTIC_TEST
Intervention: Spirometry
Description: Absolute FEV1 is measured in every patient using a handheld spirometer

Intervention type: DIAGNOSTIC_TEST
Intervention: Spirometry
Description: Absolute FEV1 is measured in every patient using a handheld spirometer

Intervention type: DIAGNOSTIC_TEST
Intervention: Spirometry
Description: Absolute FEV1 is measured in every patient using a handheld spirometer
Study: NCT03518008

Intervention type: DEVICE
Group type: OTHER
Intervention: verofilcon A contact lenses
Description: Investigational daily disposable soft contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: somofilcon A contact lenses
Description: Commercially available daily disposable soft contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: somofilcon A contact lenses
Description: Commercially available daily disposable soft contact lenses
Study: NCT03054675

Intervention type: DIAGNOSTIC_TEST
Intervention: Spirometry
Description: Absolute FEV1 is measured in every patient using a handheld spirometer
Study: NCT00472004

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined (Totelle)
Description: 17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined, 1 Daily, 1 year duration
Study: NCT01296516

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Non-intervention group
Description: A pedometer and written material on a healthy lifestyle.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face to face
Description: Motivational meetings held once per week; Behavioral sessions weill be led by a trained interventionist.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telehelath Group
Description: Participants will speak to Trestletree personnel once a week via phone.
Study: NCT01150214

Intervention type: PROCEDURE
Intervention: DE-MRI
Description: Using Delayed-Enhancement Magnetic Resonance Imaging (DE-MRI) to identify fibrotic and scarred cardiac tissue. DE-MRI is a non-invasive method of identifying the extent and the distribution of structural remodeling or fibrosis and scarring associated with atrial fibrillation both pre- and post-ablation.
Study: NCT01289925

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Selenium
Description: 200 micrograms of selenium (in the form of selenium methionine) in tablet form taken orally daily for 8 weeks. Capsule molds with inert coating.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill Placebo
Description: Placebo supplements in the same capsule mold as selenium and coated with the same inert coating. 1 tablet daily for 8 weeks.
Study: NCT03086785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: apatinib 500mg qd po or combined capecitabine 1000mg/m2 bid d1-14 q3w
Study: NCT05005858

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alveolar ridge splitting
Description: Patients with Kennedy Class I. and II. mandibles with insufficient bone width were included in this study. Ridge splitting was carried out with the use of a piezoelectric surgery device by preparing osteotomies and after mobilization of the buccal cortical by placing an autologous bone block harvested from the retromolar region as a spacer between the buccal and lingual cortical plates. Block-grafts were stabilized by osteosynthesis screws. Implant placement was carried out after a 3-month healing period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Creating osteotomies with piezoelectric device
Description: Osteotomies were carried out with piezoelectric surgery device (NSK Variosurg3 Ultrasonic Bone Surgery System, NSK Europe GmbH, Eschborn, Germany)
Study: NCT02479854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asmakast
Description: 1 chewable tablet contains 5 mg montelukast

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Singulair
Description: 1 chewable tablet contains 5 mg montelukast
Study: NCT00472004

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tibolone (Livial)
Description: Tibolone 2.5 mg 1 daily, 1 year duration
Study: NCT01232764

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exposure to multi-disciplinary wound care team
Description: Phase 1: In Person Support (3 mths)~Advance Practice Nurses (APNs) affiliated with Enhanced Multi-Disciplinary visit LTC facilities on a weekly basis. The APN may communicate with other members of an EMDT via telephone or online.EMDTs will collectively teach and mentor LTC facility wound care teams throughout the study.~Phase 2: Remote Support (2-11 mths) In the second phase, EMDTs will support LTC facility staff remotely via telephone and online communication, visiting the facilities on an as needed basis only.~All PU treatment will be based on RNAO evidence-based guidelines (updated in 2007)contextualized to the LTC setting.
Study: NCT01656850

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Almond diet first, then NCEP Diet
Description: whole almonds will be incorporated into a control diet which is a NCEP step 2 diet. Whole almonds will replace 20% daily calorie intake. Subjects were assigned to receive almond diet for 12 weeks after a 2-weeks run-in period. After washout 2 weeks, change diet to NCEP Diet for 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NCEP diet first, then Almond diet
Description: NCEP diet first, then Almond diet. Subjects were assigned to receive NCEP diet for 12 weeks after a 2-weeks run-in period. After washout 2 weeks, change diet to almond diet for 12 weeks
Study: NCT00325234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 600 mg/m\^2, administered intravenously (IV) every 21 days until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 mg\*min/mL, administered IV every 21 days until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1200 mg/m\^2 gemcitabine, administered IV on day 1 and day 8 every 21 days until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: 30 mg/m\^2 vinorelbine administered IV on day 1 and day 8 every 21 days until disease progression or unacceptable toxicity.
Study: NCT00461539

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Those participants receiving standard care will be referred to special programs as needed to reduce their involvement in risky health behaviors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral health intervention
Description: Participants assigned to the health education intervention will attend 10 weekly education sessions that will be led by trained health educators. Parents or guardians may be asked to attend sessions depending on their interest in the intervention and the age of the youth participant. Topics covered will include teenage smoking, alcohol and drug abuse, risky sexual behaviors, and obesity. Cognitive-behavioral strategies, role playing, and media clips will be used to stimulate discussion and involvement in the intervention.
Study: NCT01888289

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotretinoin
Description: Isotretinoin Capsules,40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Isotretinoin Capsules,40 mg
Study: NCT02402452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voxilaprevir
Description: 100 mg tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voxilaprevir
Description: 100 mg tablet administered orally
Study: NCT01389440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine and Erlotinib
Description: Administration of gemcitabine (300mg/m2/weekly)with Erlotinib (100 mg/daily) and radiotherapy (45 Gy/daily) after a period of infusion with a full dose of Gemcitabine (1.000mg/m2/weekly) and Erlotinib (100 mg/daily)
Study: NCT04277988

Intervention type: DEVICE
Intervention: Ultrasonography
Description: Length of Posterior Longitudianl Ligament, Ligamentum Flavum and Interlaminar distance visible in paramedian longitudinal view during lumbar spine ultrasonography in cross legged position will be compared to standard sitting position.

Intervention type: DEVICE
Intervention: Ultrasonography
Description: Length of Posterior Longitudianl Ligament, Ligamentum Flavum and Interlaminar distance visible in paramedian longitudinal view during lumbar spine ultrasonography in cross legged position will be compared to standard sitting position.
Study: NCT00792610

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hepatitis B vaccine
Description: Recombinant HBsAg, 20mcg/ml/vial (GSK) one vial IM at Day 0, Month 1, month 6 during follow-up, respectively.
Study: NCT02059148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2835219
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2835219
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2835219
Description: Administered orally.
Study: NCT00691236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: 4mg IV 3 weekly for 6 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: 4mg IV 3 weekly for 6 doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard chemotherapy
Description: Adriamycin + Cisplatinum and Ifosfamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard chemotherapy
Description: Adriamycin + Cisplatinum and Ifosfamide
Study: NCT05355506

Intervention type: DEVICE
Intervention: Application
Description: Knowledge \& record
Study: NCT03397576

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ATHENA
Description: Adherence Through Home Education and Nursing Assessment (ATHENA), is an evidence-based ART adherence intervention delivered in the patient's home by nurses and peer educators working in teams.
Study: NCT00323830

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine, cisplatin, Radiotherapy (+/-)
Description: Capecitabine, cisplatin + Radiotherapy (randomized)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine, cisplatin, Radiotherapy (+/-)
Description: Capecitabine, cisplatin + Radiotherapy (randomized)
Study: NCT04163393

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention
Description: PCI with robotic assistance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention using R-One assistance
Description: PCI with robotic assistance
Study: NCT00811564

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution
Description: 1 drop of study medication taken approximately 12 hours apart, dosed 2 times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: latanoprost 0.005%
Description: 1 drop of study medication taken once daily
Study: NCT01862172

Intervention type: OTHER
Group type: OTHER
Intervention: Additional MRI
Study: NCT04619706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FSD201
Description: Tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FSD201
Description: Tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets matched to FSD201 for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets matched to FSD201 for oral administration.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care for Covid-19
Description: Standard of care for Covid-19 as determined by site PI
Study: NCT04036981

Intervention type: DRUG
Intervention: Botulinum toxin type A
Description: Injection of botulinum toxin A into the spastic elbow flexor muscle or muscles
Study: NCT04619706

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care for Covid-19
Description: Standard of care for Covid-19 as determined by site PI

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care for Covid-19
Description: Standard of care for Covid-19 as determined by site PI
Study: NCT00003196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: Undergo cytoreductive chemotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo TBI
Study: NCT04036981

Intervention type: DRUG
Intervention: Botulinum toxin type A
Description: Injection of botulinum toxin A into the spastic elbow flexor muscle or muscles

Intervention type: DRUG
Intervention: Botulinum toxin type A
Description: Injection of botulinum toxin A into the spastic elbow flexor muscle or muscles
Study: NCT02266355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Omalizumab 300 mg SQ every 2 weeks
Study: NCT02946034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Viekira Pak ± ribavirin
Description: 12 weeks treatment with AbbVie Viekira Pak ± ribavirin
Study: NCT00003196

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo allogeneic PBSC transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given IV or PO
Study: NCT02946034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavyret
Description: 8 or 12 weeks treatment with AbbVie Mavyret
Study: NCT00507013

Intervention type: DEVICE
Group type: OTHER
Intervention: QuickClose device
Study: NCT00003196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo allogeneic PBSC transplant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic allogeneic lymphocytes
Description: Undergo DLI
Study: NCT02362724

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sapphire
Description: silicone hydrogel contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pearl
Description: silicone hydrogel contact lens
Study: NCT04863391

Intervention type: DIAGNOSTIC_TEST
Intervention: Referrable versus Non Referral AMD diagnostic test
Description: Artificial intelligence read reports Referrable versus Non Referral AMD

Intervention type: DIAGNOSTIC_TEST
Intervention: Referrable versus Non Referral AMD diagnostic test
Description: Artificial intelligence read reports Referrable versus Non Referral AMD
Study: NCT00264199

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GLP-1
Description: iv. by weight (1.0 pmol/kg/min )

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: same rate of infusion as GLP-1
Study: NCT03715803

Intervention type: DEVICE
Intervention: Calistar A mesh to treat anterior and apical POP
Description: Single incision surgery using Calistar A mesh to treat anterior and apical pelvic prolapses

Intervention type: DEVICE
Intervention: Calistar S mesh to treat anterior and apical POP
Description: Single incision surgery using Calistar S to treat anterior and apical pelvic prolapses
Study: NCT00717249

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: galyifilcon A control lens
Description: Marketed daily wear contact lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: galyfilcon A with a silver additive
Description: Investigational daily wear contact lens
Study: NCT01102036

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cultura L casei F19, acidophilus La5 , B lactis Bb 12
Description: 2 weeks consumption,250 ml/day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Yoghurt without probiotics
Description: Yoghurt without probiotics
Study: NCT03169335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1101
Description: targeted vascular endothelial growth factor (VEGF) monoclonal antibodies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avastin®
Description: targeted vascular endothelial growth factor (VEGF) monoclonal antibodies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 175 mg/m2, IV (in the vein) following investigational product on day 1 of each 21 day cycle. Number of cycles 4-6.
Study: NCT00530621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzastaurin
Description: 1125 milligrams (mg) loading dose then 500 mg, oral, daily Cycle 1 (28 days), subsequent cycles 21 days, until disease progression

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral, daily
Study: NCT01424553

Intervention type: OTHER
Group type: OTHER
Intervention: Prevention and follow-up of the patients pulmonary parameters
Description: Respiratory symptoms and lung function will be evaluated in very low birth weight and term infants, born in 1997 and included in the French EPIPAGE cohort.
Study: NCT02371499

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei DG
Description: the patients will receive 1 capsule of Lactobacillus casei DG (Enterolactis plus®) twice daily for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the patients will receive 1 capsule of product without bacteria (Enterolactis placebo) twice daily for 4 weeks
Study: NCT00000439

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium valproate
Description: subjects were randomized to sodium valproate vs placebo. Serum sodium valproate was monitored. This intervention was added on treatment as usual which was defined as being on lithium carbonate and also attending individual dual recovery counseling.
Study: NCT00530621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 milligrams per square meter (mg/m\^2), intravenous (IV), day 8 Cycle 1 (28 days), day 1 subsequent cycles (21 days), until disease progression

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pemetrexed
Description: 500 milligrams per square meter (mg/m\^2), intravenous (IV), day 8 Cycle 1 (28 days), day 1 subsequent cycles (21 days), until disease progression
Study: NCT01646268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: Transdermal Patch~Content:~2 mg /24 h (10 cm\^2), 4 mg /24 h (20 cm\^2), 6 mg /24 h (30 cm\^2), 8 mg /24 h (40 cm\^2)~For early-stage Parkinson's disease, receive Rotigotine patches in escalating weekly dose (starting with daily doses 2 mg/24 h to 8 mg/24 h) for a maximum 4-week Titration Period, then 24 week maintenance period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: Transdermal Patch~Size:~10 cm\^2, 20 cm\^2, 30 cm\^2, 40 cm\^2~Subjects randomized to placebo will receive matching placebo patches
Study: NCT02753582

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: SOD+Gliadin Capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03690375

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Broad Band Light (BBL)
Description: Sciton's BBL treatment using a new protocol that utilizes a 590nm, 560nm, and skintyte filter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Broad Band Light (BBL)
Description: Sciton's BBL treatment using a new protocol that utilizes a 590nm, 560nm, and skintyte filter
Study: NCT04327869

Intervention type: DEVICE
Intervention: Magnetically controlled capsule endoscopy
Description: The subjects swallowed the capsule with water in the left lateral position. When capsule enter stomach cavity, subject was asked to sit up and ingested 4 g aerogenic powder with 5 ml water to distend the stomach, and performed gastric baseline examinations to identify the lesions. After baseline examination, subjects ingested dyed sucralfate gel and performed the first-time examination. The examination was repeated at 30 min intervals, until dyed sucralfate gel disappeared completely.

Intervention type: DEVICE
Intervention: Magnetically controlled capsule endoscopy
Description: The subjects swallowed the capsule with water in the left lateral position. When capsule enter stomach cavity, subject was asked to sit up and ingested 4 g aerogenic powder with 5 ml water to distend the stomach, and performed gastric baseline examinations to identify the lesions. After baseline examination, subjects ingested dyed sucralfate gel and performed the first-time examination. The examination was repeated at 30 min intervals, until dyed sucralfate gel disappeared completely.